Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 1 of 45
PLAINTIFFS BAYER AG, BAYER HEALTHCARE AG, AND BAYER PHARMACEUTICALS CORP.'S TRIAL EXHIBIT LIST
TRIAL EXHIBIT NO. DEPOSITION EXHIBIT NO.
DATE
DESCRIPTION Certified Copy of USPN 4,990,517, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Certified Copy of USPN 4,990,517: Certificate of Correction Certified Copy of the Prosecution History of USPN 4,990,517, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Prosecution History of USPN 4,990,517: File Cover and Examiner Search Notes Prosecution History of USPN 4,990,517: Priority Application DE 3824072.6 (7/15/1988) (German) Prosecution History of USPN 4,990,517: Priority Application DE 3824072.6 (7/15/1988) (English) Prosecution History of USPN 4,990,517: Priority Application DE 3906365.8 (3/1/1989) (German)
BATES RANGE
OBJECTION(S)1
PTX-001
2/5/1991
BL020-002557-002615
DDX 027**
PTX001-A
4/25/1995
BL020-002613
PDX 068**
PTX-002
BL020-000332-001720
DDX 096**, DDX 121**
Incomplete
PTX002-A PTX002-B PTX002-C PTX002-E 7/15/1988
BL020-000334-000335
PDX 058**
Incomplete
BL020-000714-000844
DDX 046**
7/15/1988
BL020-000896-001025
3/1/1989
BL020-000533-000713
DDX 048**
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 1 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 2 of 45
PTX002-F PTX002-G PTX002-H PTX002-I PTX002-J PTX002-K PTX002-L PTX002-M PTX002-N PTX002-O PTX002-P PTX002-Q
3/1/1989 6/30/1989 6/30/1989 6/30/1989 6/30/1989 3/28/1990 4/4/1990 4/26/1990
Prosecution History of USPN 4,990,517: Priority Application DE 3906365.8 (3/1/1989) (English) Prosecution History of USPN 4,990,517: Prosecution Transmittal Prosecution History of USPN 4,990,517: Application (USSN 375,434) Prosecution History of USPN 4,990,517: Claims as Filed Prosecution History of USPN 4,990,517: Combined Declaration and Power of Attorney Prosecution History of USPN 4,990,517: Search Results Prosecution History of USPN 4,990,517: Office Action Prosecution History of USPN 4,990,517: Examiner Interview Summary Record Prosecution History of USPN 4,990,517: USPTO Communication Providing English Translation Prosecution History of USPN 4,990,517: Declaration re Translation of German Priority Documents Prosecution History of USPN 4,990,517: Amendment with Attachment Prosecution History of USPN 4,990,517: Examiner Interview Summary Record
BL020-001027-001212 BL020-000337 BL020-000338-000528 BL020-000513-000527 BL020-000529-000530 BL020-000845-000851 BL020-000852-000859 BL020-000890 BL020-000891; BL020-000861000876 Incomplete PDX 059** DDX 074** Illegible -- Damaged DDX 047**
5/4/1990
5/10/1990
BL020-001026
7/19/1990
BL020-000892-000895; BL020000877-000879 BL020-001217
PDX 060**
8/10/1990
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 2 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 3 of 45
PTX002-R PTX002-S PTX002-U PTX002-V PTX002-W
8/27/1990
Prosecution History of USPN 4,990,517: Notice of Allowability and Examiner's Amendment Prosecution History of USPN 4,990,517: Notice of Allowance and Issue Fee Due Prosecution History of USPN 4,990,517: Issue Fee Transmittal Prosecution History of USPN 4,990,517: European Search Report Prosecution History of USPN 4,990,517: Information Disclosure Statement with PTO Form 1449 and European Search Report Prosecution History of USPN 4,990,517: PTO Form 1449 with Examiner's Initials Prosecution History of USPN 4,990,517: USPTO Communication Acknowledging Receipt of Information Disclosure Statement Prosecution History of USPN 4,990,517: Request for Certificate of Correction Prosecution History of USPN 4,990,517: Letter of Correction Prosecution History of USPN 4,990,517: Request for Certificate of Correction Prosecution History of USPN 4,990,517: Application for Patent Term Extension
BL020-001214-001216
8/27/1990 10/31/1990 11/7/1990
BL020-001213 BL020-001219-001220 BL020-001230-001234 BL020-001221; BL020-001563; BL020-001230-001234 DDX 053** DDX 136** DDX 054**, DDX 136** Incomplete
11/16/1990
PTX002-X
2/8/1991
BL020-001563
Incomplete
PTX002-Y
2/11/1991
BL020-001562
PDX 066**
Incomplete
PTX002-Z PTX002-AA PTX002-BB PTX002-CC
3/2/1992
BL020-001564-001566
Hearsay Incomplete Incomplete Improper Attachment DDX 064**, PDX 067** Relevance
3/5/1992
BL020-001567-001569
2/16/1995
BL020-001571-001575
1/28/1999
BL020-001578-001691
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 3 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 4 of 45
PTX002-DD PTX002-EE PTX002-FF PTX002-GG PTX002-HH PTX002-II
3/11/2004
Prosecution History of USPN 4,990,517: Notice of Final Determination re Patent Term Extension Prosecution History of USPN 4,990,517: Statutory Disclaimer Prosecution History of USPN 4,990,517: Certificate of Patent Term Extension Prosecution History of USPN 4,990,517: Request for Expedited Certificate of Correction Prosecution History of USPN 4,990,517: Certificate of Correction Prosecution History of USPN 4,990,517: Disclaimer Certified Copy of USPN 5,607,942, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Certified Copy of the Prosecution History of USPN 5,607,942, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Prosecution History of USPN 5,607,942: Declaration of KlausDieter Bremm
BL020-001695-001696
3/29/2004 9/16/2004
BL020-001703-001704 BL020-001698
7/7/2005 7/72005 7/14/2005
BL020-001706-001707 BL020-001708 BL020-001705
PTX-003
3/4/1997
BL020-002616-002669
PDX 051**, DDX 052**
PTX-004
BL020-001721-002479
DDX 122**
PTX004-A
12/2/1994
BL020-001937-001941
DDX 041**
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 4 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 5 of 45
PTX004-B PTX004-C PTX004-E PTX004-F PTX004-G PTX004-H PTX004-I
3/20/1995
Prosecution History of USPN 5,607,942: Request for Continuing Application Prosecution History of USPN 5,607,942: Declaration with Respect to Divisional Application Prosecution History of USPN 5,607,942: Application (USSN 737,631) Prosecution History of USPN 5,607,942: Combined Declaration and Power of Attorney Prosecution History of USPN 5,607,942: Preliminary Amendment with Attachment Prosecution History of USPN 5,607,942: Preliminary Amendment Prosecution History of USPN 5,607,942: Declaration of KlausDieter Bremm Prosecution History of USPN 5,607,942: Attachment to and References Cited in 7/20/1995 Bremm Declaration
BL020-001924-001927
3/20/1995
BL020-001918
3/20/1995
BL020-001727-001917
3/20/1995
BL020-001919-001923 BL020-001928-001930; BL020001937-001941 BL020-001931-001936 BL020-001942-001951 DDX 055**, DDX 126** DDX 058** DDX 044**
3/20/1995 5/19/1995 7/20/1995
PTX004-J
BL020-001952-001958; BL020002364-002377
DDX 044**
PTX004-K PTX004-L PTX004-M
8/1995
Prosecution History of USPN 5,607,942: Third Preliminary Amendment Prosecution History of USPN 5,607,942: Information Disclosure Statement with Attachment Prosecution History of USPN 5,607,942: Information Disclosure Statement with Attachment
BL020-002037-002040
DDX 057**
8/1995
BL020-002027-002034
DDX 056**
8/30/1995
BL020-002041-002045
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 5 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 6 of 45
PTX004-O PTX004-P PTX004-Q PTX004-R PTX004-S PTX004-U PTX-005 PTX-006 PTX-007 PTX-008 PTX-009 PTX-010
11/1/1995
Prosecution History of USPN 5,607,942: Sprung Horn Communication Attaching Appeal Decisions Prosecution History of USPN 5,607,942: Office Action Prosecution History of USPN 5,607,942: Amendment Prosecution History of USPN 5,607,942: Examiner Interview Summary Record Prosecution History of USPN 5,607,942: Notices of Allowability and Allowance Prosecution History of USPN 5,607,942: Issue Fee Transmittal Stipulation And Order Stipulation And Order Excerpt of Dr. Reddy's ANDA: Moxifloxacin Hydrochloride Tablets 400 mg CV of Professor Edward C. Taylor CV of Thomas J. Perun, Ph.D.
BL020-002046-002068
DDX 059**
Incomplete
3/8/1996 6/6/1996 7/1/1996
BL020-002069-002074 BL020-002172-002181 BL020-002171 DDX 062** Hearsay
7/18/1996
BL020-002182-002183
10/11/1996 6/13/2005 7/6/2005 12/10/2003
BL002184-002185 PDX 151** PDX 152** DRLMOX-005020-005044 BL021-000878-000927 BL021-000868-000877 BL021-000127-000234
Illegible
Relevance Hearsay Hearsay Hearsay
1/2006
CV of Dr. George G. Zhanel
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 6 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 7 of 45
PTX-011
PTX011-A PTX011-B PTX011-C PTX011-E
9/10/1990
Prosecution History of USPN 5,059,597, Petersen et al., 7-(4-Oxa or 4-Thia-2,7Diazabicyclo[3.3.0]Oct-2-en-3-yl)-3Quinolone-and-NaphthyridoneCarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Prosecution History of USPN 5,059,597: Application (USSN 580,906) Prosecution History of USPN 5,059,597: Preliminary Amendment with Attachment Prosecution History of USPN 5,059,597: Preliminary Amendment with Attachment Prosecution History of USPN 5,059,597: Information Disclosure Statement with Attachment Prosecution History of USPN 5,416,096, Petersen et al., 7-(1Pyrrolidinyl)-3-Quinolonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer)
DRLMOX 036285-036599
DRLMOX 036290-036480
9/10/1990
DRLMOX 036486-036489 DRLMOX 036492-036493; DRLMOX 036491; DRLMOX 036533-036534 DRLMOX 036501-036508 DDX 065**, DDX 085** Relevance Incomplete
10/1/1990
2/14/1991
PTX-012
DRLMOX 038215-038608
PTX012-A PTX012-B
7/30/1991 2/4/1992
Prosecution History of USPN 5,416,096: Preliminary Amendment Prosecution History of USPN 5,416,096: Office Action Prosecution History of USPN 4,840,954, Petersen et al., 6,7Disubstituted 1-Cyclopropyl-1,4Dihydro-4-Oxo-1,8-Naphthyridine-3Carboxylic Acids (Bayer)
DRLMOX 038417-038425 DRLMOX 038428-038437
PTX-013
DRLMOX 034193-035335
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 7 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 8 of 45
PTX013-A PTX013-B PTX013-C PTX013-E
12/31/1985 4/22/1986 7/22/1986 11/3/1986
Prosecution History of USPN 4,840,954: Application (USSN 815,440) Prosecution History of USPN 4,840,954: Office Action Prosecution History of USPN 4,840,954: Amendment Prosecution History of USPN 4,840,954: Office Action Prosecution History of USSN 07/298,459, Petersen et al., Quinolone- and Naphthyridone Carboxylic Acid Derivatives, Process for their Production, Antibacterial Compositions and Feed Additives Containing Them (Bayer) Prosecution History of USSN 07/298,459: Application Prosecution History of USSN 07/298,459: Examiner Interview Summary Record Prosecution History of USSN 07/298,459: Letter with Attachment Prosecution History of USSN 07/298,459: Office Action with Attachment Prosecution History of USSN 07/298,459: Declaration of KlausDieter Bremm Prosecution History of USSN 07/298,459: Amendment
DRLMOX 034198-034242 DRLMOX 034374-034382 DRLMOX 034479-034484 DRLMOX 034491-034496 PDX 100**
PTX-014
DRLMOX 040312-040972
DDX 049**
PTX014-A PTX014-B PTX014-C PTX014-E PTX014-F PTX014-G
1/18/1989 1/10/1990 1/23/1990 4/23/1990
DRLMOX 040315-040382 DRLMOX 040604 DRLMOX 040605-040607 DRLMOX 040675-040679 Hearsay
8/16/1990 8/22/1990
DRLMOX 040878-040882 DRLMOX 040868-040875
DDX 045**
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 8 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 9 of 45
PTX014-H PTX014-I PTX014-J PTX-015
11/19/1990
Prosecution History of USSN 07/298,459: Office Action with Attachment Prosecution History of USSN 07/298,459: Declaration of KlausDieter Bremm Prosecution History of USSN 07/298,459: Amendment Prosecution History of USPN 5,071,999, Schenke et al., Preparation of 2,7Diazabicyclo[3.3.0]Octanes (Bayer)
DRLMOX 040886-040890 Hearsay
1/17/1991 2/11/1991
DRLMOX 040926-040928 DRLMOX 040920-040925 DDX 140, DDX 140-A
DRLMOX 042552-042923
PTX015-A PTX015-B PTX015-C PTX-016 PTX-017
4/17/1989 4/10/1990 12/10/1991 4/16/2003 6/30/1989
Prosecution History of USPN 5,071,999: Priority Application P3912509.2 Prosecution History of USPN 5,071,999: Application USPN 5,071,999, Schenke et al., Preparation of 2,7Diazabicyclo[3.3.0]Octanes (Bayer) Minutes of New Product Development Review Meeting Prosecution History of LeA 26 108EP: Original Specification Prosecution History of LeA 26 108EP: Claims as Filed Prosecution History of LeA 26 108EP: European Patent Office Search Report Prosecution History of LeA 26 108EP: Office Action
DRLMOX 042736-042813 DRLMOX 042555-042629 DRLMOX 042870-042890 DRLMOX 016457-016478 BL001-026355-026526 PDX 016 Relevance Relevance No Translation Relevance No Translation
PTX-018
6/30/1989
BL001-026527-026540
PTX-019
11/7/1990
BL001-026627-026630 Relevance No Translation
PTX-020
11/17/1992
BL001-026622-026626
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 9 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 10 of 45
PTX-021
7/19/1993
Prosecution History of LeA 26 108EP: Letter from Bailly to the European Patent Office re: Amended Claims Prosecution History of LeA 26 108EP: Amended Patent Claims for the Contracting States: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, and SE Prosecution History of LeA 26 108EP: Amended Patent Claims for the Contracting State: ES Prosecution History of LeA 26 108EP: Amended Patent Claims for the Contracting State: GR Prosecution History of LeA 26 108EP: Office Action EP 0350733 B1, Petersen et al., 7(1-Pyrrolidinyl)-3-Quinolone- and Naphthyridone-Carboxylic-Acid Derivatives, Method for Their Preparation and for Substituted Mono- and Bi-cyclic Pyrrolidine Intermediates, and Their Antibacterial and Feed Additive Compositions (Bayer) Moxifloxacin in Practice, vol. 1
BL001-026611-026612
Relevance No Translation
PTX-022
7/19/1993
BL001-026216-026229
Relevance No Translation
PTX-023
7/19/1993
BL001-026230-026237
Relevance No Translation Relevance No Translation Relevance No Translation
PTX-024
7/19/1993
BL001-026238-026250
PTX-025
10/19/1993
BL001-026608-026610
PTX-026
8/20/1997
BL001-028133-028262
PTX-027
1999
BL007-001000-001109
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 10 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 11 of 45
PTX027-A
1999
Tillotson and Blondeau, Today's Community Respiratory Tract Infections: A Challenge Appropriate for Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 1:1-11 (1999) Petersen, et. al., The Synthesis and In Vitro and In Vivo Antibacterial Activity of Moxifloxacin (BAY 122039), A New 8-Methoxyquinolone, Moxifloxacin in Practice, Maxim Medical, 1:13-26, (1999) Felmingham et al., In Vitro Activity of Moxifloxacin (BAY 12-8039), A Novel 8-Methoxyquinolone, Comparable with Ofloxacin and Other Antibiotics, Moxifloxacin in Practice, Maxim Medical, 1:27-37 (1999) Kayser et al., In Vitro Activity of Moxifloxacin Against Invasive Pneumococcal Strains Compared with Other Antimicrobials, Moxifloxacin in Practice, Maxim Medical, 1:39-47 (1999) Verbist and Verhaegen, In Vitro Activity of Moxifloxacin (BAY 128039), A Novel 8-Methoxyquinolone, Against Gram-Positive Clinical Isolates, Moxifloxacin in Practice, Maxim Medical, 1:49-56 (1999)
BL007-001010-001020
Hearsay Relevance
PTX027-B
1999
BL007-001022-001035
Hearsay Relevance
PTX027-C
1999
BL007-001036-001046
Hearsay Relevance
PTX027-E
1999
BL007-001048-001056
Hearsay Relevance
PTX027-F
1999
BL007-001058-001065
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 11 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 12 of 45
PTX027-G
1999
Durham et al., Mechanism of Activity of Moxifloxacin Against Staphylococcus aureus In Vitro, Moxifloxacin in Practice, Maxim Medical, 1:57-62 (1999) Durham et al., Preferred Targets of Moxifloxacin in Staphylococcus aureus, Moxifloxacin in Practice, Maxim Medical, 1:63-69 (1999) Gillespie, The Activity of Moxifloxacin and Other Fluoroquinolones Against Mycobacterium tuberculosis and Other Mycobacteria, Moxifloxacin in Practice, Maxim Medical, 1:71-79 (1999) Dalhoff, In Vivo Lack of Emergence of Resistance to Moxifloxacin in Staphylococcus aureus and Streptococcus pneumoniae, Moxifloxacin in Practice, Maxim Medical, 1:81-89 (1999) Doucet-Populaire et al., In Vitro Activity of Moxifloxacin, A Novel 8Methoxyquinolone, Compared with the Activities of Macrolides, Ciprofloxacin and Levofloxacin Against Bordetella pertussis, Moxifloxacin in Practice, Maxim Medical, 1:91-97 (1999) Moxifloxacin in Practice, vol. 2
BL007-001066-001071
Hearsay Relevance
PTX027-H
1999
BL007-001072-001078
Hearsay Relevance
PTX027-I
1999
BL007-001080-001088
Hearsay Relevance
PTX027-J
1999
BL007-001090-001098
Hearsay Relevance
PTX027-K
1999
BL007-001100-001106
Hearsay Relevance
PTX-028
1999
BL007-002000-002112
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 12 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 13 of 45
PTX028-A
1999
von Keutz and Schlüter, Moxifloxacin and the Liver: Results of Preclinical Investigations, Moxifloxacin in Practice, Maxim Medical, 2:1-4 (1999) MacGowan, Pharmacodynamics of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 2:5-15 (1999) Wiedemann, In Vitro Pharmacodynamics of Moxifloxacin Against Respiratory Tract Pathogens, Moxifloxacin in Practice, Maxim Medical, 2:17-25 (1999) Jacobs and Dalhoff, Efficacy of Moxifloxacin, A New 8Methoxyquinolone, Against Group 1 and Group 2 Mycoplasma pneumoniae Strains in a Guinea-Pig Respiratory Model, Moxifloxacin in Practice, Maxim Medical, 2:27-35 (1999) Garcia-Rodriguez et al., In Vitro Activity of Moxifloxacin Against Respiratory Tract Pathogens, Moxifloxacin in Practice, Maxim Medical, 2:37-48 (1999) Debbia et al., Activity of Moxifloxacin Against Antibiotic-Resistant Streptococcus pyogenes, Moxifloxacin in Practice, Maxim Medical, 2:49-60 (1999)
BL007-002010-002013
Hearsay Relevance
PTX028-B
1999
BL007-002014-002024
Hearsay Relevance
PTX028-C
1999
BL007-002026-002034
Hearsay Relevance
PTX028-E
1999
BL007-002036-002044
Hearsay Relevance
PTX028-F
1999
BL007-002046-002057
Hearsay Relevance
PTX028-G
1999
BL007-002058-002069
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 13 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 14 of 45
PTX028-H
1999
M'Zali et al., Differential Selection of Quinolone Resistance by New Quinolone in Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus, Moxifloxacin in Practice, Maxim Medical, 2:61-69 (1999) Nichterlein et al., The Activity of Moxifloxacin, A New 8Methoxyquinolone, Against Strains of Salmonellae and Listeria monocytogenes In Vitro, In Mouse Infections and In Infected Tissue Cells, Moxifloxacin in Practice, Maxim Medical, 2:71-82 (1999) Vohr et al., An Investigation into the Phototoxic Potential of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 2:83-90 (1999) Tillotson and Blondeau, StructureActivity-Function Evaluation of Fluoroquinolones, Moxifloxacin in Practice, 2:91-101 (1999) Moxifloxacin in Practice, vol. 3. Read, Clinical Overview: Moxifloxacin in Community Respiratory Tract Infections, Moxifloxacin in Practice, Maxim Medical, 3:1-14 (2000)
BL007-002070-002078
Hearsay Relevance
PTX028-I
1999
BL007-002080-002091
Hearsay Relevance
PTX028-J
1999
BL007-002092-002099
Hearsay Relevance
PTX028-K
1999
BL007-002100-002110
Hearsay Relevance Hearsay Relevance
PTX-029
2000
BL007-003000-003089
PTX029-A
2000
BL007-003010-003023
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 14 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 15 of 45
PTX029-B
2000
Stass et al., The Effect of Food on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers, Moxifloxacin in Practice, Maxim Medical, 3:15-23 (2000) von Keutz, Moxifloxacin: Effects on Joints and Tendons in Experimental Animals, Moxifloxacin in Practice, Maxim Medical, 3:25-31 (2000) Morrissey and Hunter, The Importance of the Ability of an Antimicrobial Agent to Kill the Pathogen, Moxifloxacin in Practice, Maxim Medical, 3:33-48 (2000) Felmingham et al., The In Vitro Activity of Moxifloxacin Against 817 Isolates of Streptococcus pneumoniae Collected from 27 Centres Throughout Great Britain and Ireland During the 1997 - 1998 Cold Season, Moxifloxacin in Practice, Maxim Medical, 3:49-56 (2000) King et al., The Comparative In Vitro Activity of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 3:57-63 (2000)
BL007-003024-003032
Hearsay Relevance
PTX029-C
2000
BL007-003034-003040
Hearsay Relevance
PTX029-E
2000
BL007-003042-003057
Hearsay Relevance
PTX029-F
2000
BL007-003058-003065
Hearsay Relevance
PTX029-G
2000
BL007-003066-003072
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 15 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 16 of 45
PTX029-H
2000
Gemmell, Some Features of the Interaction Between Moxifloxacin, Granulocyte-Colony Stimulating Factor and Neutrophils in Relation to the Intracellular Survival of Salmonella typhimurium, Moxifloxacin in Practice, Maxim Medical, 3:65-72 (2000) Herrington et al., Factors Affecting the In Vitro Activity of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 3:73-79 (2000) Mitscher et al., Structure-Activity Relationships of the Newer Quinolone Antibacterial Agents, Quinolones, (Fernandes ed.), Prous, 3-20 (1989) Sanchez et al., Quinolone Antibacterial Agents. Synthesis and Structure-Activity Relationships of 8Substituted Quinolie-3-Carboxylic Acids and 1,8-Naphthyidine-3Carboxylic Acids, J. Med. Chem., 31:983-991 (1988) Sanchez et al., Quinolone Antibacterial Agents. Synthesis and Structure-Activity Relationships of 8Substituted Quinolie-3-Carboxylic Acids and 1,8-Naphthyidine-3Carboxylic Acids, J. Med. Chem., 31:983-991 (1988) (date stamped copy)
BL007-003074-003081
Hearsay Relevance
PTX029-I
2000
BL007-003082-003088
Hearsay Relevance
PTX-032
1989
PDX 032
Hearsay Relevance
PTX-033
1988
PDX 033
Hearsay Relevance
PTX033-D
5/8/1988
BL021-000799-000812
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 16 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 17 of 45
PTX-034
1986
Domagala et al., New StructureActivity Relationships of the Quinolone Antibacterials Using the Target Enzyme. The Development and Application of a DNA Gyrase Assay, J. Med. Chem., 29:394-404 (1986) USPN 4,284,629, Grohe et al., Process for the Preparation of 4Pyridone-3-Carboxylic Acids and/or Derivatives Thereof (Bayer) USPN 4,341,784, Matsumoto et al., Naphthyridine Derivatives (Dainippon) EP Application 0106489 A2, Culbertson et al., Antibacterial Agents (Warner-Lambert) EP Application 0106489 B1, Culbertson et al., Antibacterial Agents (Warner-Lambert) USPN 4,638,067, Culberson et al., Antibacterial Agents (WarnerLambert) USPN 4,777,175, Culbertson et al., Antibacterial Agents (WarnerLambert) EP Application 0181521 A1, Tone et al., Antimicrobial 1-Subtitued Phenyl-4-Oxoquinolone-3Carboxylic Acid Compounds (Otsuka)
PDX 034
Hearsay Relevance
PTX-035
8/18/1981
BL020-000321-000331
Hearsay Relevance
PTX-036
7/27/1982
DRLMOX 030245-030254
PDX 036
PTX-037
4/25/1984
DRLMOX 027092-027216
PDX 037
PTX-038
4/25/1984
BL021-001191-001246
PTX-039
1/20/1987
SH-000001-009319-009355
PTX-040
10/11/1988
BL021-000086-000121
PTX-041
5/21/1986
PDX 041
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 17 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 18 of 45
PTX-042
1988
Excerpt from Abstracts of the Annual Meeting of the American Society for Microbiology 1988, abstracts A-13 through A-17 re: PD 117,596 and PD 127,391 Cohen et al., In Vitro Activity of PD 117596 and PD 127391, New Quinolone Antimicrobic Agents, Annual Meeting of the American Society for Microbiology 1988, Abstract A17 Excerpt from Abstracts of the Annual Meeting of the American Society for Microbiology 1988, cover and table of contents (date stamped copy) Smith et al., In Vitro Activities of PD 117,596 and Reference Antibiotics Against 448 Clinical Bacterial Strains, Antimicrob. Agents Chemother., 32(9):1450-1455 (1988) King et al., The In Vitro Activity of PD 127,391, A New Quinolone, J. Antimicrob. Chemother., 22:135-141 (1988) EP Application 0195316 A1, Irikura et al., Quinolonecarboxylic Acid Derivatives (Kyorin) EP Application 0241206 A2, Iwata et al., Quinoline-3-Carboxylic Acid Derivatives (Sankyo) BL021-000016-000058
PDX 042
Hearsay Relevance Incomplete
PTX042-A
1988
Hearsay Relevance Incomplete
PTX042-D
4/12/1988
BL021-000859-000862
Hearsay Relevance Incomplete
PTX-043
9/1988
PDX 043
Hearsay Relevance
PTX-044
1988
PDX 044
Hearsay Relevance
PTX-045
3/6/1986
PTX-046
10/14/1987
DRLMOX 008890-009078
PDX 046, DDX 028**
Typo in certification
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 18 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 19 of 45
PTX-047
1985
Program and Abstracts of the 25th ICAAC: Abstract 565 Synthesis and Antibacterial Activity of AT-3765, a New Pyridonecarboxylic Acid Antibacterial Agent 14th International Congress of Chemotherapy: Abstract P-35-41, AT-3295, A New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-Activity Relationships Domagala et al., 7-Substituted 5Amino-1-Cyclopropyl-6,8-Difluoro1,4-Dihydro-4-Oxo-3Quinoinecarboxylic Acids: Synthesis and Biological Activity of a New Class of Quinolone Antibacterials, J. Med. Chem., 31:503-506 (1988) Domagala et al., 7-Substituted 5Amino-1-Cyclopropyl-6,8-Difluoro1,4-Dihydro-4-Oxo-3Quinoinecarboxylic Acids: Synthesis and Biological Activity of a New Class of Quinolone Antibacterials, J. Med. Chem., 31:503-506 (1988) (date stamped copy) Minutes Meeting from Project: Substances for Chemical Therapy Minutes from the AKF "Antibacterial Therapy" Meeting on 9/23/1987
PDX 047
Hearsay Relevance
PTX-048
6/1985
PDX 048
PTX-050
1988
PDX 050
Hearsay Relevance
PTX050-D
3/10/1988
BL021-000813-000822
Hearsay Relevance
PTX-051
8/1/1985
BL018-142240-142244
Relevance Incomplete No Translation Relevance No Translation
PTX-052
10/22/1987
BL002-096559-096562
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 19 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 20 of 45
Relevance No Translation Relevance No Translation Hearsay Relevance Incomplete No Translation Hearsay Hearsay Lack of Specific Description General Objection Pending Inspection of Documents Hearsay Lack of Specific Description General Objection Pending Inspecting of Documents
PTX-053
9/20/1993
Minutes from the AK-F "Quinolones" Meeting Quinolonecarboxylic Acids: Number of Patents (Graph) Quinolonecarboxylic Acids: Number of Patents (Graph)
BL004-034177-034199
PTX-054
1/1994
BL005-020346-020346
PTX-055
1/20/1994
BL005-020279-020279
PTX-056
Petersen Patent Abstract Card Collection Box 1
PTX-057
Petersen Patent Abstract Card Collection Box 2
PTX-058
10/14/1987
Patent Abstract Card for EP 241206, New 7-Heterocyclic-1,4-Dihydro-4Oxoquinolone-3 Carboxylic Acid Cpds- Useful as Antibacterial Agents with Activity Against Resistant Strains (Sankyo) USPN 4,649,144, Matsumoto et al., Antibacterial 7-(3-Amino-1Pyrrolidinyl)-1-Cyclopropyl-6-Fluoro1,4-Dihydro-4-Oxo-1,8Naphthyridine-3-Carboxylic Acid Derivatives (Dainippon) Manual of Patent Examining Procedure: Foreword (5th ed.)
BL005-038418-038420
Hearsay
PTX-059
3/10/1987
BL021-000059-000085
PTX-060
8/1983
DRLMOX 042166-70
Illegible Incomplete
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 20 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 21 of 45
PTX-061
5/19/1988
Manual of Patent Examining Procedure: Chapter 800 (5th ed., 8th rev.) Manual of Patent Examining Procedure: Chapter 2239 (5th ed., 12th rev.)
DRLMOX 041664-041692
PDX 061 Incomplete
PTX-062
BL021-000928-000929
PTX-063
10/2005
Manual of Patent Examining Procedure: Foreword (8th ed., 4th rev.) Manual of Patent Examining Procedure: Chapter 800 (8th ed., 4th rev.) Prosecution History of USPN 4,990,517: Table of Contents
BL021-001073-001079 BL021-001073-001078; BL021001083-001154 DRLMOX 041013 SH_000001-000025 BL021-000235-000244 DRLMOX 035842-035848 DRLMOX 041633-041663 PDX 069 PDX 070 PDX 065
Relevance
PTX-064 PTX-065 PTX-066 PTX-067 PTX-069 PTX-070
10/2005
Relevance
11/12/1990 8/17/2005 2/25/1991 5/1986
Prosecution History of USPN 4,990,517: Letter from Bailly and Danner to Sprung Horn Expert Report of Lowell S. Young with paragraph 20 redacted Prosecution History of USPN 5,059,597: Examiner's Action Manual of Patent Examining Procedure: Chapter 2000 (5th ed., 3rd rev.) DRL's Objections and Responses to Plaintiffs' First Set of Interrogatories (1-8)
Relevance
PTX-071
2/11/2005
Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 21 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 22 of 45
PTX-072
4/7/2005
PTX-073
6/20/2005
Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.'s Responses to Plaintiffs Bayer AG, Bayer Healthcare AG and Bayer Pharmaceuticals Corporation's Second Request for Admission (Nos. 12-26) Dr. Reddy's Response to Bayer's Contention Interrogatories 37-38 and 42-44 Dr. Reddy's First Supplemental Response to Bayer's Interrogatories (Nos. 25, 28, 31, 39-41 and 46) Notice of Dr. Reddy's Pursuant to Fed. R. Civ. P. 30(b)(6) BE Application 887574, Surugadai, et al., Dérivés de l'acide quinoléinecarboxylique et procédé pour leur préparation (Kyorin) UK Patent Application GB 2093018A, Irkura, et al., 6,8Difluoro-Quinoline Carboxylic Acid Derivatives (Kyorin) SciFinder Scholar Entries Press Release: TB Alliance and Bayer Launch Historic Global Drug Trials for Tuberculosis Report: Synthesis of Substituted Piperazines- New Basic Heterocycles for Gyrase Inhibitor Substitution in Pos. 7 BL021-001260-001284 PDX 001
Relevance
Relevance Relevance Relevance Hearsay Relevance No Translation Late Production Hearsay Relevance Late Production Hearsay Relevance Late Production Hearsay Relevance Late Production Hearsay Relevance No Translation
PTX-074 PTX-075
8/3/2005 5/11/2005
PTX-076
6/15/1981
PTX-077
8/25/1982
BL021-001247-001259
PTX-078
BL021-001354-001405
PTX-079
10/18/2005
BL021-001406-001409
PTX-080
11/13/1987
BL004-037074-037099
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 22 of 45
Case 1:04-cv-00179-SLR
PTX-081 PTX-101 12/2/1987
Document 108-7
Filed 03/03/2006
Page 23 of 45
Bottle of Avelox® 400 mg Tablets Compound Card for PEW 6412B Excerpt from Laboratory Notebook re: SES 695 Excerpt from Laboratory Notebook re: SES 721 USPN 4,571,396, Hutt et al., Antibacterial Agents (WarnerLambert) EP Application 0159174 A2, Hutt et al., Substituted Naphthyridine-, Quinolone- and BenzoxazineCarboxylic Acids as Antibacterial Agents and Processes for Their Production (Warner-Lambert) Compound Card for SEW 2554 BL005-033591 PDX 101 Hearsay Relevance No Translation
PTX-102 PTX-103 PTX-105
11/3/1987 12/10/1987 2/18/1986
BL009-009402 BL009-009432
PDX 102 PDX 103 PDX 105 Hearsay Relevance
PTX-106
10/23/1985
BL021-001539-001602
Hearsay Relevance
PTX-140
BL002-008043
PDX 140
Hearsay Relevance No Translation Hearsay Relevance No Translation Hearsay Relevance No Translation Hearsay Relevance No Translation
PTX-141
4/6/1989
Compound Card for SEW 2532
BL002-008048
PDX 141
PTX-142
5/14/1993
Annotated Compound Card for PEW 7645B
BL005-032755
PDX 142
PTX142-A
5/14/1993
Compound Card for PEW 7645B
BL005-032755
PDX 142**
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 23 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 24 of 45
PTX-160
Collection of Bayer data
BL002-016090-016092; BL002015364; BL002-039374-039377; BL004-0036010 BL002-053026; BL002-016090016092; BL002-053419-053420; BL002-053431-053436 BL002-016190; BL005-032769; BL002-028585-028588; BL002028611; BL005-016145; BL018033385-033404; BL002-022251; BL002-015411; BL002-022002022003; BL002-022023; BL018036136; BL002-015376-015377; BL002-023467-023470; BL002023485; BL002-024301-024303; BL002-038381-038382; BL002038331-038332; BL002-038399038400; BL018-072235-072243; BL018-034030-034032; BL002038137-038139; BL002-074197; BL018-033228-033237; BL002015492; BL002-022416; BL002022429; BL005-033530; BL005017276; BL002-027301-027303; BL002-027325; BL005-032230; BL005-032018; BL011-015123015141; BL002-015256; BL005034006; BL002-093024-093026; BL018-111095; BL005-033734; BL018-032451-032481; BL002015469; BL002-022310-022311
Hearsay Relevance No Translation Hearsay Relevance No Translation
PTX-161
Collection of Bayer data
PTX-162
Collection of Bayer data
PDX 162
Hearsay Relevance Incomplete No Translation
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 24 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 25 of 45
Hearsay Relevance Incomplete No Translation
PTX-163
Collection of Bayer data
PTX-164
Collection of Bayer data
PTX-165
Collection of Bayer data
BL002-014006; BL005-016118; BL002-074178; BL005-016101; BL005-016088; BL002-015489; BL005-017427; BL002-015241015243 BL002-001000-017113; BL002074142-075006; BL004-036003036043; BL004-036351-036373; BL005-013016-013017; BL005013308; BL005-016000-017520; BL005-032000-034372; BL005051757-051758; BL018-013009013017; BL018-016265-016296; BL018-035000-037283; BL018038303-038313; BL018-039031039563; BL018-086000-086402; BL018-089000-089243; BL018090084-090107; BL018-090145090214; BL018-092081-092217; BL018-104000-104081; BL018108004-108013; BL018-109081109100; BL018-110000-111461 BL008-012351-012365; BL002023023-023026; BL002-035382035384; BL018-085021; BL008012124-012159; BL002-046505; BL002-024331-024332; BL002094120-094121; BL002-094077; BL002-035343-035345; BL002014006
Hearsay Relevance Incomplete No Translation
Hearsay Relevance Incomplete No Translation
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 25 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 26 of 45
PTX-166
Collection of Bayer data
BL005-032230; BL002-028585028588; BL002-029458-029460; BL002-029461-029483; BL002029484; BL002-042018-042022; BL002-043082-043086; BL002043209-043212; BL002-051341051355; BL002-051356-051369; BL002-051387-051400; BL002053255-053267; BL002-053343053361; BL002-053437-053443; BL002-053460-053464; BL002053466-053470; BL002-054072054074; BL002-055188-055190; BL002-056135-056141; BL002062105-062108; BL002-093066093069; BL002-094080; BL005015098-015099; BL005-040367040368; BL005-044265-044284; BL005-053426-053427; BL008017261-017267; BL008-018319018340 BL018-036159; BL018-051253; BL018-036149; BL018-052053; BL018-036108
Hearsay Relevance Incomplete No Translation
PTX-167
Collection of Bayer data
Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation
PTX-168
Collection of Bayer data
BL018-036287; BL018-039245; BL018-035251
PTX-169
Collection of Bayer data
BL004-005282; BL004-005694; BL004-005713-005714
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 26 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 27 of 45
PTX-170
Compound Card for PEW 6348
BL005-051757
PTX-171
Collection of Bayer data
BL002-009295; BL002-014009; BL002-014014-014015; BL002014021-014031
Hearsay Relevance Incomplete No Translation Illegible Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation Hearsay Relevance No Translation Hearsay Relevance No Translation
PTX-172
Collection of Bayer data
BL002-016201; BL002-028585-88; BL002-028611; BL002-015505; BL002-022432-33; BL002-022457
PTX-173
Bayer data In vitro antibacterial activity of the new quinolone BAY Y3118 against clinical isolates (draft), with cover letter Comparative In Vitro Activity of BAY Y3118, A New 4-Quinolone, and Ciprofloxacin Against Mycobacterium tuberculosis and M. avium complex (draft)
BL002-107015-107016
PTX-174
1/26/1994
BL002-130322-130337
PTX-175
10/26/1993
BL002-129263-129270
Hearsay Relevance
PTX-176
Collection of Bayer data
BL005-033319; BL005-033675; BL005-015105-015107; BL002133112; BL018-028370-028373; BL018-029131-029133; BL002038444-038445; BL018-121025121043; BL002-039135-039139; BL002-114248
Hearsay Relevance Incomplete No Translation
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 27 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 28 of 45
Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation
PTX-177
10/6/1992
BAY Y3118 IND Excerpt
BC004-001072; BC004-001166001170
DDX 021**
PTX-178
10/6/1992
BAY Y3118 IND Excerpt
BC004-001072; BC004-001134-41
DDX 021**
PTX-179
Collection of Bayer data
BL018-036084; BL018-033260033270; BL002-008043; BL002022262-022263; BL002-022279 BL002-015171; BL002-024388024390; BL002-024411; BL002016145; BL002-028419-028422; BL002-028451; BL018-036102; BL018-033260-033270; BL002008046; BL002-022262-022263; BL002-022279
PTX-180
Collection of Bayer data
Hearsay Relevance Incomplete No Translation
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 28 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 29 of 45
PTX-181
Collection of Bayer data
BL005-033780; BL018-028326028332; BL005-033726; BL018028199-028204; BL005-033575; BL018-078305-078307; BL005033529; BL018-070211-070220; BL002-038005; BL002-038262038264; BL018-034030-034032; BL005-033539; BL002-039685039687; BL005-033533; BL018078084-078086; BL005-033483; BL018-070086-070088; BL005033535; BL018-078174-078177; BL005-033515; BL018-078047078051; BL005-033490; BL018070179-070181; BL005-033486; BL018-070028-070029; BL005033449; BL018-070053-070054; BL005-033474; BL018-070074070075; BL005-033441; BL002038002-038004; BL005-033409; BL002-038490-038492; BL005033344; BL002-038259-038261; BL005-033343; BL002-038256038258; BL002-038017; BL005033327; BL002-039593; BL005033323; BL002-039610-039613; BL005-033232; BL002-040598040599; BL005-033319; BL002133112; BL002-039477-BL002039479; BL005-033315; BL002039435-039437; BL005-033310; BL002-040673-040674; BL005033293; BL002-039423-039425;
PDX 181
Hearsay Relevance Incomplete No Translation
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 29 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 30 of 45
BL005-033287; BL002-039303039305; BL005-033285; BL002040665-040667; BL005-033278; BL002-039235-039237; BL005033270; BL002-039131-039133; BL005-033252; BL002-094077; BL005-033254; BL002-039070039073; BL005-033247; BL002040624-040625; BL005-033034; BL002-041312-041314; BL005033033; BL002-041308-041310; BL005-032753; BL002-133113; BL005-032740; BL002-043384; BL005-032718; BL002-043356; BL005-032711; BL002-043317; BL005-032709; BL002-043322; BL005-032672; BL002-094082; BL002-012063; BL018-070078070079 PTX181-A BL005-033033; BL002-041308041310 BL002-015376-015377; BL002038137-038139; BL018-028370028373; BL018-029131029133;BL002-038444-038445; BL018-121025-121043; BL002038412-038413; BL002-041540041543; BL018-089174-089184 Hearsay Relevance Incomplete No Translation
Collection of Bayer data
PTX-182
Collection of Bayer data
Hearsay Relevance Incomplete No Translation
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 30 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 31 of 45
PTX-201
8/2003
Allen et al., Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an in vitro Pharmacodynamic Model, Antimicrob. Agents Chemother., 47(8):2606-2614 (2003) Andrews et al., Concentrations of Levofloxacin (HR 355) in the Respiratory Tract Following a Single Oral Dose in Patients Undergoing Fibre-Optic Bronchoscopy, J. Antimicrob. Chemother., 40:573-577 (1997) Ashby et al., An Investigation of the Hydrophobicity of the Quinolones, Correspondence Section, Journal of Antimicrob. Chemother., 16:805-810 (1985) Berger, Synthesis of Some Conformationally Restricted Analogues of Fentanyl, J. Med. Chem., 20:600-602 (1977) Bermudez et al. Activity of Moxifloxacin by Itself and in Combination with Ethambutol Rifabutin, and Azithromycin in vitro and in vivo Against Mycobacterium avium, Antimicrob. Agents Chemother., 45:217-222 (2001)
BL021-000576-000584
Hearsay Relevance Late Production
PTX-202
1997
BL021-000965-000969
Hearsay Relevance
PTX-203
1985
BL021-000245-000248
Hearsay Relevance
PTX-204
1977
BL021-000698-000700
Hearsay Relevance
PTX-205
1/2001
BL021-000471-000476
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 31 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 32 of 45
PTX-206
3/1996
Bermudez et al., Activities of BAY Y3118, Levofloxacin and Ofloxacin Alone or in Combination with Ethambutol against Mycobacterium avium Complex in vitro, in Human Macrophages and in Beige Mice, Antimicrob. Agents Chemother., 40:546-551 (1996) Bermudez et al., SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease, Antimicrob. Agents Chemother., 48:3556-3558 (2004) Birkofer & Feldmann, Über Bicyclische Dilactame, Justus Liebigs, Ann. der Chemie, 677:154157 (1964) Blondeau et al., Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae, Antimicrob. Agents Chemother., 45:433-438 (2001) Borne et al., Conformationally Restrained Fentanyl Analogues. 2. Synthesis and Analgetic Evaluation of Perhydro-1,6-naphthyridin-2ones, J. Med. Chem., 27:1271-1275 (1984)
BL021-000701-000706
Hearsay Relevance
PTX-207
9/2004
BL021-000477-000479
Hearsay Relevance
PTX-208
1964
SH_000001-004018-004019
PTX-209
2/2001
BL021-000377-000382
Hearsay Relevance
PTX-210
1984
BL021-000707-000711
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 32 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 33 of 45
PTX-211
2002
Boswell et al., Comparison of the In Vitro Activities of Several New Fluoroquinolones Against Respiratory Pathogens and Their Abilities to Select Fluoroquinolone Resistance, J. Antimicrob. Chemother., 50:495-502 (2002) Chapman et al., Routes of Quinolone Permeation in Escherichia coli, Antimicrob. Agents Chemother., 32:438-442 (1988) Chen et al., Decreased Susceptibility of Streptococcus pneumonia to Fluoroquinolones in Canada, N. Engl. J. Med., 341:233239 (1999) Cook et al., Concentrations of OPC17116, A New Fluoroquinolone Antibacterial, in Serum and Lung Compartments, J. Antimicrob. Chemother., 35:317-326 (1995) Cornett and Wentland, Quinolone Antibacterial Agents, Ann. Rpts. Med. Chem., 21(ch. 14):139-148 (1986) Davidson et al., Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia, N. Engl. J. Med., 346:747-750 (2002)
BL021-000585-000592
Hearsay Relevance
PTX-212
4/14/1988
BL021-000823-000828
Hearsay Relevance
PTX-213
7/22/1999
BL021-000712-000718
Hearsay Relevance
PTX-214
1995
BL021-000970-000979
Hearsay Relevance
PTX-215
1986
BL021-001410-001421
Hearsay Relevance
PTX-216
3/7/2002
BL021-000719-000722
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 33 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 34 of 45
PTX-217
6/2001
Doern et al., Antimicrobial Resistance Among Clinical Isolates of Streptococcus pneumoniae in the United States During 1999-2000, Including a Comparison of Resistance Rates Since 1994-1995, Antimicrob. Agents Chemother., 45:1721-1729 (2001) Domagala et al., 1-Ethyl-7-[3[(ethylamino)methyl]-1-pyrrolidinyl]6,8-difluoro-1,4-dihydro-4-oxo-3quinoline-carboxylic Acid. New Quinolone Antibacterial with Potent Gram-Positive Activity, J. Med. Chem., 29:445-448 (1986) Evans et al., Methods for Drug Discovery : Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists, J. Med. Chem., 31:2235-2246 (1988) Fernandes and Chu, Quinolone Antibacterial Agents, Ann. Rpts. Med. Chem., 23 (ch. 14):133-140 (1988) Fernandes and Chu, Quinolones, Ann. Rpts. Med. Chem., 22 (ch. 12):117-126 (1987) Fernandes, Mode of Action, and In Vitro and In Vivo Activities of the Fluoroquinolones, J. Clin. Pharmacol., 28:156-168 (1988)
BL021-000541-000549
Hearsay Relevance
PTX-218
1986
BL021-000391-000394
Hearsay Relevance
PTX-219
1988
BL021-000723-000734
Hearsay Relevance
PTX-220
9/13/1988
BL021-000843-000858
Hearsay Relevance
PTX-221
1987
BL021-001422-001433
Hearsay Relevance
PTX-222
3/16/1988
BL021-000829-000842
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 34 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 35 of 45
PTX-223
4/2004
Florea et al. Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations Against Streptococcus pneumoniae, Antimicrob. Agents Chemother., 48:1215-1221 (2004) Fuller and Low, A Review of Streptococcus pneumoniae Infection Treatment Failures Associated with Fluoroquinolone Resistance, Clin. Infect. Dis., 41:118-121 (2005) Gatifloxacin - The Drug Class of Quinolones is Growing, Zeitschrift für Chemotherapie, 22:36 (2001) Gatifloxacin - The Drug Class of Quinolones is Growing, Zeitschrift für Chemotherapie, 22:36 (2001) (Translation) Gemifloxacin (Factive), The Medical Letter, 46(1192):78-79 (2004) Gosling et al., The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis, Am. J. Respir. Crit. Care Med., 168:13421345 (2003) Gotfried et al., Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Health Adult Subjects, Chest, 119:1114-1122 (2001)
BL021-000746-000752
Hearsay Relevance
PTX-224
7/2005
BL021-000735-000738
Hearsay Relevance
PTX-225
2001
BL020-000201-000203
Hearsay Relevance No Translation Hearsay Relevance No Translation Hearsay Relevance
PTX-226
2001
BL020-000204-000207
PTX-227
9/27/2004
BL021-000786-000788
PTX-228
2003
BL021-000602-000605
Hearsay Relevance
PTX-229
4/2001
BL021-000944-000952
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 35 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 36 of 45
PTX-230
1987
Heifets et al., Determination of MICs of Conventional and Experimental Drugs in Liquid Medium by the Radiometric Method Against Mycobacterium Avium Complex, Drugs. Expl. Clin. Res., 13(9):529538 (1987) Hirai et al., Differences in Susceptibility to Quinolones of Outer Membrane Mutants of Salmonella typhimurium and E. coli, Antimicrob. Agents and Chemother., 29:535-538 (1986) Kennedy, Managing the Drug Discovery/Development Interface, Drug Discovery Today 2:10, 436444 (1997) Klein et al., Uber die Synthese und pharmakologische Wirkung cyclischer Analoga des Fentanyls, Arch. Pharmaz., 308:910-916 (1975) Kreis et al., A Comparison of Moxifloxacin and Azithromycin in the Treatment of Acute Exacerbations of Chronic Bronchitis, JCOM, 7(12):3337 (2000) Létourneau et al., Gatifloxacin (TequinTM): Hypoglycemia and Hyperglycemia, Can Adv React News. Health Can., 13:1-2 (2003)
BL021-000662-000671
Hearsay Relevance
PTX-231
3/1986
BL021-000254-000257
Hearsay Relevance
PTX-232
10/10/1997
BL021-001182-001190
Hearsay Relevance
PTX-233
1975
BL021-000739-000745
Hearsay Relevance No Translation
PTX-234
12/2000
BL021-000753-000757
Hearsay Relevance
PTX-235
7/2003
BL021-000536-000540
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 36 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 37 of 45
PTX-236
2001
Lister and Sanders, Pharmacodynamics of Moxifloxacin, Levofloxacin and Sparfloxacin Against Streptococcus pneumoniae, J. Antimicrob. Chemother., 47(6):811-818 (2001) Man et al., Fluoroquinolone Phototoxicity: A Comparison of Moxifloxacin and Lomefloxacin in Normal Volunteers, J. Antimicrob. Chemother., 43 (supp. B):77-82 (1999) Mouton et al., Standardization of Pharmacokinetic/Pharmacodynamic (PK/PD) Terminology for AntiInfective Drugs: an Update, J. of Antimicro. Chemother. 55:601-607 (2005) Nagai et al., Single- and Multi-Step Resistance Selection Study of Gemifloxacin Compared with Trovafloxacin, Ciprofloxacin, Gatifloxacin and Moxifloxacin in Streptococcus pneumoniae, J. Antimicrob. Chemother., 48(3):365374 (2001) Nuermberger et al., Moxifloxacincontaining Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis, Am. J. Respir. Crit. Care. Med. 169:421-426 (2004)
BL021-000611-000618
Hearsay Relevance
PTX-237
1999
BL021-000554-000559
Hearsay Relevance
PTX-238
2005
BL021-000930-000936
Hearsay Relevance
PTX-239
2001
BL021-000619-000628
Hearsay Relevance
PTX-240
2004
BL021-000953-000958
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 37 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 38 of 45
PTX-241
2005
Pier and Ramphal, P. aeruginosa, Principles and Practice of Infectious Diseases, 6th ed. Chapter 216 (2005) Pletz et al., Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study, Antimicrob Agents Chemother 48:780-782 (2004) Rubinstein, History of Quinolones and Their Side Effects, Chemother., 47(suppl. 3):3-8 (2001) Soman et al., Concentrations of Moxifloxacin in Serum and Pulmonary Compartments Following a Single 400mg Oral Dose in Patients Undergoing Fibre-Optic Bronchoscopy, J. Antimicrob. Chemother., 44(6):835-838 (1999) Wentland and Cornett, Quinolone Antibacterial Agents, Ann. Rpts. Med. Chem., 20(ch. 15):145-154 (1985) Wilson et al., Short-term and Longterm Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis, Chest, 125(3):953-964 (2004)
BL021-001434-001465
Hearsay Relevance
PTX-242
3/2004
BL021-000635-000637
Hearsay Relevance
PTX-243
2001
BL021-000406-000411
Hearsay Relevance
PTX-244
1999
BL021-000572-000575
Hearsay Relevance
PTX-245
1985
BL021-001466-001479
Hearsay Relevance
PTX-246
3/2004
BL021-000412-000423
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 38 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 39 of 45
PTX-247
1996
Wise and Honeybourne, A Review of the Penetration of Sparfloxacin into the Lower Respiratory Tract and Sinuses, J. Antimicrob. Chemother., 37(suppl. A):57-63 (1996) Wise, Maximizing Efficacy and Reducing the Emergence of Resistance, J. Antimicrob. Chemother., 51(suppl. S1):37-42 (2003) Woodcock et al., In Vitro Activity of BAY 12-8039, a New Fluoroquinolone, Antimicrobial Agents and Chemother. 41(1):101106 (1997) Wright, Cefsulodin, Drug Intel. and Clin. Pharm. 20:845-849 (1986) Zhanel and Noreddin, Pharmacokinetics and Pharmacodynamics of the New Fluoroquinolones: Focus on Respiratory Infections, Curr. Opin. Pharmacol., 1:459-463 (2001) Zhanel et al., Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002, Antimicrob. Agents Chemother., 47(6):1867-1874 (2003)
BL021-000937-000943
Hearsay Relevance
PTX-248
2003
BL021-000959-000964
Hearsay Relevance
PTX-249
1/1997
BL021-000789-000794
Hearsay Relevance
PTX-250
11/1986
BL021-000863-000867
Hearsay Relevance
PTX-251
2001
BL021-000676-000680
Hearsay Relevance
PTX-252
6/2003
BL021-000648-000655
Hearsay Relevance
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 39 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 40 of 45
PTX-253
2001
Zhanel et al., In Vitro Pharmacodynamic Modeling Simulating Free Serum Concentrations of Fluoroquinolones Against Multidrug-resistant Streptococcus pneumoniae, J. Antimicrob. Chemother., 47:435-440 (2001) Zhanel et al., Pharmacodynamic Activity of Fluoroquinolones Against Ciprofloxacin-Resistant Streptococcus pneumoniae, J. Antimicrob. Chemother., 49:807-812 (2002) Zhanel, Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection, Cur. Infect. Dis. Rpts., 3:29-34 (2001) Drawing of ciprofloxacin by Dr. Remmel EP Application 0132845 A2, Matsumoto et al., Novel 1,8Naphthyridine Derivatives, and Process for Preparation Thereof (Dainippon) Bayer AG Organisationplan Status Report 1985- AKF "Antibacterial Therapy" Status Report 1986- AKF "Antibacterial Therapy"
BL021-000686-000691
Hearsay Relevance
PTX-254
2002
BL021-000656-000661
Hearsay Relevance
PTX-255
2001
BL021-000692-000697
Hearsay Relevance
PTX-257
PDX 257
Hearsay Relevance
PTX-328
2/13/1985
BL021-001285-001353
No Translation
PTX1011 PTX1013 PTX1014
1/1/1988 1/21/1986 1/26/1987
BL010-005257-005493 BL002-100310-100343 BL002-100266-100309
DDX 011 DDX 013 DDX 014
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 40 of 45
Case 1:04-cv-00179-SLR
PTX1015 PTX1016 PTX1017 PTX1018 PTX1019 PTX1020 PTX1022
Document 108-7
Filed 03/03/2006
Page 41 of 45
1/26/1988 1/16/1989 1/18/1990 1/16/1991 1/9/1992 1/5/1994
Status Report 1987- AKF "Antibacterial Therapy" Status Report 1988- AKF "Antibacterial Therapy" Status Report 1989- AKF "Antibacterial Therapy" Status Report - AK Research "Antibacterial Therapy" 1990 Status Report - AK Research "Antibacterial Therapy" 1991 Status Report: AK Research "Quinolones" 1993 ICAAC 1992 Poster #642, Petersen et al., BAY Y3118, A Novel 4Quinolone: Synthesis and in vitro Activity ICAAC 1992 Poster #642, Petersen et al., BAY Y3118, A Novel 4Quinolone: Synthesis and in vitro Activity (with enlargements) USPN 4,666,920, Grohe et al., Antibacterial 1,7-Diamino-1,4Dihydro-4-Oxo-3Quinolonecarboxylic Acids (Bayer) ICAAC 1992 Poster #643, Thurberg et al., In Vitro Activity of BAY Y3118, a New Quinolone
BL002-100216-100265 BL002-100063-100132 BL002-100133-100169 BL002-096340-096380 BL002-096239-096283 BL002-096010-096054
DDX 015 DDX 016 DDX 017 DDX 018 DDX 019 DDX 020 Relevance Incomplete
1992
BL009-036178
DDX 022
Illegible
PTX1022-A
1992
BL009-036178
DDX 022-A
Illegible
PTX1023
5/19/1987
DRLMOX 040973-040982
DDX 023
PTX1025
1992
SH000001-005240-005242
DDX 025
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 41 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 42 of 45
PTX1026
12/22/1992
USPN 5,173,484, Petersen et al., Quinolone- and Naphthyridone Carboxylic Acid Derivatives, Process for Their Production, Antibacterial Compositions, and Feed Additives Containing Them (Bayer) Compound Card for PEW 6902 Compound Card for PEW 6957 Compound Card for PEW 6873B Minutes Emergency Team Meeting BAY Y3118, 3/93 on 3/17/1993 Report from Bremm summarizing Daiichi DU-6859 Status Report: AK Research "Quinolones" 1994 PC 10/94 Meeting Minutes Report: BAY 11-6371 (tosylate) and BAY 12-8039 (hydrochloride): Results of Microbiological Tests Prosecution History of USSN 08/026,906: Combined Declaration and Power of Attorney Prosecution History of USSN 08/026,906: Original Specification Prosecution History of USSN 08/026,906: Declaration by Dr. Klaus-Dieter Bremm
DRLMOX 030539-030564
DDX 026
PTX1030 PTX1031 PTX1032 PTX1034 PTX1035 PTX1036 PTX1037 PTX1038 PTX1039 PTX1040 PTX1041
7/26/1990 10/4/1990 5/18/1990 1/25/1993 7/13/1994 1/16/1995 11/4/1994 3/10/1995
BL002-015256 BL002-015187 BL005-017418 BL005-047236-047247 BL002-097136-097142 BL002-097006-097043 BL002-134176-134177 BL002-134026-134081
DDX 030 DDX 031 DDX 032 DDX 034 DDX 035 DDX 036 DDX 037 DDX 038 Hearsay Hearsay
4/23/1993 3/5/1993 12/2/1994
BL001-014381-014382 BL001-014002-014135 DRLMOX 038825-038829
DDX 039 DDX 040 DDX 041
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 42 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 43 of 45
PTX1069
11/8/1994
Prosecution History of USSN 08/026,906: Letter from Briscoe (Sprung Horn) to Pross (Patent Providers) re request to deliver an Amendment and Petition for Extension of Time Prosecution History of USSN 08/026,906: Second Amendment under Rule 116 Prosecution History of USSN 08/026,906: Amendment under Rule 111 Prosecution History of USSN 08/026,906: Amendment Under Rule 116 Prosecution History of USSN 08/026,906: Notice of Appeal From the Primary Examiner to the Board of Patent Appeals and Interferences Report: 1-Cyclopropyl-8-MethoxyQuinolonecarboxylic Acid Petersen's Laboratory Notebook for PEW 6731 - PEW 6875 Petersen's Laboratory Notebook for PEW 6876 - PEW 7000 Petersen, The Evolution of Quinolones: From Nalidixic Acid to the Third-Generation Quinolones, Pharmazie in unserer Zeit, 30(5):376-381 (2001) Petersen et al., Synthesis and in vitro Activity of BAY 12-8039, A New 8-Methoxyquinolone, Poster F001
SH_000001-004600
DDX 069
PTX1070 PTX1071 PTX1072
12/15/1994
SH_000001-005134-005137
DDX 070
2/16/1994
SH_000001-005176-005187
DDX 071
11/8/1994
SH_000001-005153-005163
DDX 072
PTX1073 PTX1075 PTX1078 PTX1079
11/10/1994
SH_000001-005149-005150
DDX 073 No Translation
6/2/1993
BL005-012468-012500 BL008-011000-011521 BL008-012000-012469
DDX 075 DDX 078 DDX 079
PTX1080
2001
DRLMOX 030951-030956
DDX 080
PTX1084
BL005-019300
DDX 084
Illegible
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 43 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 44 of 45
PTX1091
10/22/1991
USPN 5,059,597, Petersen et al., 7(4-Oxa or 4-Thia-2,7Diazabicyclo[3.3.0]Oct-2-en-3-yl)-3Quinolone-and-NaphthyridoneCarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) USPN 5,416,096, Petersen et al., 7(1-Pyrrolidinyl)-3Quinolonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Patent File LeA 26 108-USA-3CIP Dainippon Abstracts (AT-3295) Recent Advances in Chemotherapy, Proceedings of the 14th International Congress of Chemotherapy (Kyoto, 1985) Nakamura et al., In vitro, Antibacterial Activity of AT-3295, a New Pyridonecarboxylic Acid Derivative, Proceedings of the 14th International Congress of Chemotherapy, Kyoto (1985) Minami et al., In vivo Effect of AT3295 Against Experimental Infections, Proceedings of the 14th International Congress of Chemotherapy, Kyoto (1985)
BL001-011005-011111
DDX 091
PTX1092 PTX1093 PTX1115
5/16/1995
BL001-013005-013058
DDX 092
BL001-014000-014393
DDX 093
1985
DRLMOX 041901-041909
DDX 115
PTX1115-A
1985
DRLMOX 041904-041905
DDX 115**
PTX1115-B
1985
DRLMOX 041906-041907
DDX 115**
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 44 of 45
Case 1:04-cv-00179-SLR
Document 108-7
Filed 03/03/2006
Page 45 of 45
PTX1115-C
1985
Matsumoto et al., AT-3295, a New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-Activity Relationships, Proceedings of the 14th International Congress of Chemotherapy, Kyoto (1985) Petersen, Quinolone Antibiotics: The Development of Moxifloxacin (Galley Proof)
DRLMOX 041908-041909
DDX 115**
PTX1135 PTX1135-A 2006
BL020-000223-000278 BL021-001480-001538
DDX 135 DDX 135**
Petersen, Quinolone Antibiotics: The Development of Moxifloxacin Albrecht, Development of Antibacterial Agents of Nalidixic Acid Type, Progress in Drug Res., vol. 21, (Jucker ed.), Birkhauser, 9-104 (1977) USPN 4,665,079, Culberson et al., Antibacterial Agents (WarnerLambert) Draft Stipulation and Order
PTX1158
8/1977
BL005-030407-030458
DDX 158
Hearsay Relevance Late Production
PTX1165 PTX1170
5/12/1987
DRLMOX 026952-026988
DDX 165 DDX 170 Not Evidence Relevance
As used in the foregoing objections, "Relevance," "No Translation" and "Illegible" refer to Federal Rules of Evidence 401, 402, ands 403; "Hearsay" refers to Federal Rules of Evidence 801, 802, and 805; "Incomplete" refers to Federal Rules of Evidence 106, 401, 402, and 403. By setting forth these objections to the documents on Bayer's Trial Exhibit list, Reddy does not concede that the descriptions of the documents on Bayer's list are necessarily accurate.
1
Reddy reserves its right to object further to documents on or added to this list on any basis that depends upon how a document is introduced, for what purpose a document is introduced, and what portion of a document is introduced.
** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT
Page 45 of 45